- By ICR Secretariat
- Posted Monday, August 3, 2020
5 FDA approval decisions to watch in the 3rd quarter
The next few months could bring the first gene therapy for hemophilia, a new type of multiple myeloma drug and an additional treatment option for a devastating muscular condition.
The Food and Drug Administration is set to make decisions on approval of all three, as well as on a closely watched arthritis pill and the first oral drug for spinal muscular atrophy, between July and September.